Literature DB >> 15471879

Surface-exposed hemophilic mutations across the factor VIII C2 domain have variable effects on stability and binding activities.

P Clint Spiegel1, Paul Murphy, Barry L Stoddard.   

Abstract

Factor VIII (fVIII) is a plasma glycoprotein that functions as an essential cofactor in blood coagulation. Its carboxyl-terminal "C2" domain is responsible for binding to both activated platelet surfaces and von Willebrand factor. We characterized the effect of 20 hemophilia-associated missense mutations across this domain (that all occur in patients in vivo) on its stability and its binding activities. At least six of these mutations were severely destabilizing, and another four caused moderate destabilization and corresponding reductions in both binding functions. One mutant (A2201P) displayed a significant reduction in its membrane binding activity but normal von Willebrand factor binding, while two others (P2300S and R2304H) caused the opposite effect. Several mutations (including L2210P, V2223M, M2238V, and R2304C) displayed near wild-type stabilities and binding activities and may instead affect mRNA splicing or alternative properties or functions of the protein. This study demonstrated that von Willebrand factor and membrane binding activities can be uncoupled and uniquely disrupted by different mutations and that either effect can lead to similar reductions in clotting activity. It also illustrated how a heterogeneous genetic disorder causes diverse molecular phenotypes that result in similar disease states.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15471879     DOI: 10.1074/jbc.M409389200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Study on the efficacy and safety of Xueyou Mixture in treating hemophilia.

Authors:  Shan-xi Liu; Lin Jiang; Yi-guo Liu; Yue-qin He; Xin Liang; Wei-wei Kong; Jing Chen
Journal:  Chin J Integr Med       Date:  2007-06       Impact factor: 1.978

2.  Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies.

Authors:  Justin D Walter; Rachel A Werther; Maria S Polozova; Julie Pohlman; John F Healey; Shannon L Meeks; Pete Lollar; P Clint Spiegel
Journal:  J Biol Chem       Date:  2013-02-15       Impact factor: 5.157

3.  Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry.

Authors:  A M Sevy; J F Healey; W Deng; P C Spiegel; S L Meeks; R Li
Journal:  J Thromb Haemost       Date:  2013-12       Impact factor: 5.824

4.  Membrane-binding properties of the Factor VIII C2 domain.

Authors:  Valerie A Novakovic; David B Cullinan; Hironao Wakabayashi; Philip J Fay; James D Baleja; Gary E Gilbert
Journal:  Biochem J       Date:  2011-04-01       Impact factor: 3.857

5.  The tertiary structure and domain organization of coagulation factor VIII.

Authors:  Betty W Shen; Paul Clint Spiegel; Chong-Hwan Chang; Jae-Wook Huh; Jung-Sik Lee; Jeanman Kim; Young-Ho Kim; Barry L Stoddard
Journal:  Blood       Date:  2007-10-26       Impact factor: 22.113

6.  Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes.

Authors:  Justin D Walter; Rachel A Werther; Caileen M Brison; Rebecca K Cragerud; John F Healey; Shannon L Meeks; Pete Lollar; P Clint Spiegel
Journal:  Blood       Date:  2013-10-01       Impact factor: 22.113

7.  Identification of 31 novel mutations in the F8 gene in Spanish hemophilia A patients: structural analysis of 20 missense mutations suggests new intermolecular binding sites.

Authors:  Adoración Venceslá; María Angeles Corral-Rodríguez; Manel Baena; Mónica Cornet; Montserrat Domènech; Montserrat Baiget; Pablo Fuentes-Prior; Eduardo F Tizzano
Journal:  Blood       Date:  2008-01-09       Impact factor: 22.113

8.  Storage of factor VIII variants with impaired von Willebrand factor binding in Weibel-Palade bodies in endothelial cells.

Authors:  Maartje van den Biggelaar; Eveline A M Bouwens; Jan Voorberg; Koen Mertens
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

9.  The 1.7 Å X-ray crystal structure of the porcine factor VIII C2 domain and binding analysis to anti-human C2 domain antibodies and phospholipid surfaces.

Authors:  Caileen M Brison; Steven M Mullen; Michelle E Wuerth; Kira Podolsky; Matthew Cook; Jacob A Herman; Justin D Walter; Shannon L Meeks; P Clint Spiegel
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

10.  Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor.

Authors:  Estelle K Ronayne; Shaun C Peters; Joseph S Gish; Celena Wilson; H Trent Spencer; Christopher B Doering; Pete Lollar; P Clint Spiegel; Kenneth C Childers
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.